Solux Calls EGM to Approve Merger with Aribio and Expand into Pharmaceuticals... Business Purpose Broadened, New Directors Strengthen Governance
Solux will hold an extraordinary general meeting on August 25, 2026 (rescheduled from July 7) to approve the merger with Aribio Co., Ltd.
The merger adds over 50 business items including pharmaceuticals, health functional foods, and cosmetics manufacturing/sales, while removing convenience store and camper rental operations.
New outside director Eunjik Lee (Yonsei University medical professor) and audit committee member Youngho Im (managing partner of Yul Jeong Law Firm) are proposed for appointment.
The merger marks Solux's official entry into the bio-pharmaceutical sector, potentially driving long-term growth.
[AI Comprehensive Analysis]The diversification through the Aribio merger could enhance enterprise value, but the absence of detailed merger terms and synergy quantification presents risks for investors.
KOSDAQ Filing Information
Filing: [Correction of Description] Resolution on Convening of General Meeting of Shareholders (Extraordinary General Meeting)